Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Boston Scientific Corporation discussed Q1 2026 results and reiterated that its announced acquisition of Penumbra is expected to close in the second half of 2026, subject to the Penumbra shareholder vote on May 6th/7th and receipt of remaining regulatory clearances. The company said guidance excludes the Penumbra transaction and noted a recent tuck-in acquisition of Valencia Technologies.
The call emphasized growth in Interventional Oncology, continued prioritization of strategic tuck-in M&A and share repurchases, and that all revenue references on the call were organic and exclude certain recent acquisitions or divestitures.
The Company Penumbra, Inc. is soliciting votes in support of the proposed merger with Boston Scientific Corporation. The Board unanimously recommends shareholders vote FOR the Merger at a Special Meeting to be held on May 6, 2026. A Form S-4 proxy statement/prospectus was declared effective on April 1, 2026.
Stockholders are urged to read the Proxy Statement/Prospectus and may obtain free copies from the SEC or the companies' investor websites.
Penumbra Inc director Harpreet Grewal reported an open-market sale of 100 shares of common stock at $328.22 per share on April 2, 2026. After this transaction, Grewal directly holds 8,719 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan, and a portion of the remaining shares is subject to vesting.
Penumbra, Inc. submitted a Rule 144 notice listing specific Common Stock transactions. The excerpt shows a 100-share lot linked to Fidelity Brokerage Services LLC with a numeric entry $32,822.00 and a separate entry showing 186 shares associated with Grewal Harpreet on 01/06/2026 with $58,151.04. Dates visible include 04/02/2026.
Penumbra, Inc. is proposing to be acquired by Boston Scientific Corporation pursuant to an Agreement and Plan of Merger dated January 14, 2026, under which Penumbra will become a wholly owned subsidiary of Boston Scientific. Each issued and outstanding Penumbra share (other than excluded or dissenting shares) will convert into the right to receive either $374.00 in cash or 3.8721 Boston Scientific Shares, subject to a proration mechanism that allocates 73.26% of shares to cash consideration and 26.74% to stock consideration.
The parties valued the consideration at $374.00 per Penumbra share at announcement. Based on shares outstanding as of March 27, 2026, Boston Scientific expects to issue approximately 43,866,267 Boston Scientific Shares and former Penumbra holders would own ~2.87% of Boston Scientific post-close. The special meeting of Penumbra stockholders is scheduled for May 6, 2026, and the proxy/prospectus contains detailed election procedures, regulatory conditions, termination fees and risk factors.
Penumbra Inc Schedule 13G/A: The Vanguard Group files an amendment reporting 0 shares beneficially owned—0% of Common Stock following an internal realignment.
The amendment explains that, effective January 12, 2026, certain Vanguard subsidiaries and business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim on 03/27/2026.
Penumbra Inc President Shruthi Narayan reported a routine tax-withholding share disposition. On the vesting of restricted stock units, 117 shares of common stock were withheld by the company to satisfy tax obligations at an indicated value of $336.18 per share. After this non-market event, Narayan directly holds 30,755 shares of Penumbra common stock, and a portion of these shares remains subject to vesting.
Penumbra Inc executive Johanna Roberts had 186 shares of Common Stock withheld by the company to cover taxes on vesting restricted stock units. The shares were valued at $336.18 per share for this tax-withholding transaction. After this non-market disposition, she directly holds 67,298 shares of Penumbra Common Stock.
This event reflects routine tax withholding related to equity compensation rather than an open-market sale or discretionary trading decision.
Penumbra Inc Chief Financial Officer Maggie Yuen reported a routine tax-related share disposition. The company withheld 186 shares of common stock at $336.18 per share to satisfy tax obligations tied to vesting restricted stock units. After this withholding, she directly holds 18,167 common shares.
Penumbra Inc’s Chief Accounting Officer Lambert Shiu reported a routine tax-related share disposition. On March 15, 2026, 150 shares of common stock were withheld by the company at $336.18 per share to satisfy tax obligations from vesting restricted stock units. After this tax-withholding transaction, Shiu directly owns 39,323 shares of Penumbra common stock and indirectly holds 300 shares through a spouse’s IRA.